Literature DB >> 11390268

Pharmacokinetics of Gadomer-17, a new dendritic magnetic resonance contrast agent.

B Misselwitz1, H Schmitt-Willich, W Ebert, T Frenzel, H J Weinmann.   

Abstract

RATIONALE AND
OBJECTIVES: Gadomer-17 is a new magnetic resonance (MR) contrast medium presently in clinical development. It is a dendritic gadolinium (Gd) chelate carrying 24 Gd ions. This study investigated the pharmacokinetic behavior of this contrast medium.
METHODS: The pharmacokinetics of Gadomer-17 were investigated in different species (rat, rabbit, dog, monkey) for up to 7 days after intravenous (i.v.) injection of 25-100 micromol/kg body weight. In addition, elimination and biodistribution were evaluated after single i.v. injection of Gadomer-17 in rats.
RESULTS: After i.v. injection Gadomer-17 distributes almost exclusively within the intravascular space without significant diffusion into the interstitial space. The volume of distribution (Vc) in the initial or alpha-phase ranged from 0.04 l/kg (rats, rabbits) to 0.06 l/kg (monkeys) and 0.07 l/kg (dogs), which reflects mainly the plasma volume. The blood/plasma concentration profile was found to be biphasic. The volume of distribution at a steady state is clearly smaller than that of other contrast media, which distribute to the extracellular space. After single i.v. injection in rats, the dendritic contrast medium was rapidly and completely eliminated from the body, mainly via glomerular filtration. No long-term accumulation or retention of the nonmetabolized agent was detectable in organs or tissues.
CONCLUSIONS: Gadomer-17 is a promising new MR contrast medium that has an intravascular distribution and a rapid renal elimination.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11390268     DOI: 10.1007/BF02668094

Source DB:  PubMed          Journal:  MAGMA        ISSN: 0968-5243            Impact factor:   2.533


  23 in total

1.  Magnetic resonance angiography with gadomer-17. An animal study original investigation.

Authors:  Q Dong; D R Hurst; H J Weinmann; T L Chenevert; F J Londy; M R Prince
Journal:  Invest Radiol       Date:  1998-09       Impact factor: 6.016

2.  MS-325: albumin-targeted contrast agent for MR angiography.

Authors:  R B Lauffer; D J Parmelee; S U Dunham; H S Ouellet; R P Dolan; S Witte; T J McMurry; R C Walovitch
Journal:  Radiology       Date:  1998-05       Impact factor: 11.105

3.  MR angiography with gadopentetate dimeglumine-polylysine: evaluation in rabbits.

Authors:  G Marchal; H Bosmans; P Van Hecke; U Speck; P Aerts; P Vanhoenacker; A L Baert
Journal:  AJR Am J Roentgenol       Date:  1990-08       Impact factor: 3.959

4.  Gadolinium-enhanced MR aortography.

Authors:  M R Prince
Journal:  Radiology       Date:  1994-04       Impact factor: 11.105

5.  Preclinical evaluation of the pharmacokinetics, biodistribution, and elimination of MS-325, a blood pool agent for magnetic resonance imaging.

Authors:  D J Parmelee; R C Walovitch; H S Ouellet; R B Lauffer
Journal:  Invest Radiol       Date:  1997-12       Impact factor: 6.016

6.  Evaluation of Gd-DTPA-labeled dextran as an intravascular MR contrast agent: imaging characteristics in normal rat tissues.

Authors:  S C Wang; M G Wikström; D L White; J Klaveness; E Holtz; P Rongved; M E Moseley; R C Brasch
Journal:  Radiology       Date:  1990-05       Impact factor: 11.105

Review 7.  Peripheral MR angiography.

Authors:  K Y Ho; T Leiner; M W de Haan; J M van Engelshoven
Journal:  Eur Radiol       Date:  1999       Impact factor: 5.315

8.  MR lymphography with a lymphotropic T1-type MR contrast agent: Gd-DTPA-PGM.

Authors:  L Harika; R Weissleder; K Poss; C Zimmer; M I Papisov; T J Brady
Journal:  Magn Reson Med       Date:  1995-01       Impact factor: 4.668

9.  Dendrimer-based metal chelates: a new class of magnetic resonance imaging contrast agents.

Authors:  E C Wiener; M W Brechbiel; H Brothers; R L Magin; O A Gansow; D A Tomalia; P C Lauterbur
Journal:  Magn Reson Med       Date:  1994-01       Impact factor: 4.668

10.  In vivo and in vitro evaluation of Gd-DTPA-polylysine as a macromolecular contrast agent for magnetic resonance imaging.

Authors:  G Schuhmann-Giampieri; H Schmitt-Willich; T Frenzel; W R Press; H J Weinmann
Journal:  Invest Radiol       Date:  1991-11       Impact factor: 6.016

View more
  26 in total

1.  3D pulmonary perfusion MRI and MR angiography of pulmonary embolism in pigs after a single injection of a blood pool MR contrast agent.

Authors:  Christian Fink; Sebastian Ley; Michael Puderbach; Christian Plathow; Michael Bock; Hans-Ulrich Kauczor
Journal:  Eur Radiol       Date:  2004-03-03       Impact factor: 5.315

2.  Measurement of kinetic parameters in skeletal muscle by magnetic resonance imaging with an intravascular agent.

Authors:  Anthony Z Faranesh; Dara L Kraitchman; Elliot R McVeigh
Journal:  Magn Reson Med       Date:  2006-05       Impact factor: 4.668

3.  Tumor microvasculature observed using different contrast agents: a comparison between Gd-DTPA-Albumin and B-22956/1 in an experimental model of mammary carcinoma.

Authors:  Federico Boschi; Pasquina Marzola; Marco Sandri; Elena Nicolato; Mirco Galiè; Silvia Fiorini; Flavia Merigo; Vito Lorusso; Linda Chaabane; Andrea Sbarbati
Journal:  MAGMA       Date:  2008-03-04       Impact factor: 2.310

4.  Magnetic resonance coronary angiography with Vasovist: in-vivo T1 estimation to improve image quality of navigator and breath-hold techniques.

Authors:  Kai Nassenstein; Kai-Uwe Waltering; Sebastian Kelle; Thomas Schlosser; Frank Breuckmann; Stefan Maderwald; Peter Hunold; Eike Nagel; Jörg Barkhausen
Journal:  Eur Radiol       Date:  2007-08-14       Impact factor: 5.315

5.  Incorporating a vascular term into a reference region model for the analysis of DCE-MRI data: a simulation study.

Authors:  A Z Faranesh; T E Yankeelov
Journal:  Phys Med Biol       Date:  2008-04-25       Impact factor: 3.609

Review 6.  Macromolecular and dendrimer-based magnetic resonance contrast agents.

Authors:  Ambika Bumb; Martin W Brechbiel; Peter Choyke
Journal:  Acta Radiol       Date:  2010-09       Impact factor: 1.990

7.  Impact of drug size on brain tumor and brain parenchyma delivery after a blood-brain barrier disruption.

Authors:  Marie Blanchette; Luc Tremblay; Martin Lepage; David Fortin
Journal:  J Cereb Blood Flow Metab       Date:  2014-02-12       Impact factor: 6.200

8.  Polymeric PARACEST agents for enhancing MRI contrast sensitivity.

Authors:  Yunkou Wu; Youfu Zhou; Olivier Ouari; Mark Woods; Piyu Zhao; Todd C Soesbe; Garry E Kiefer; A Dean Sherry
Journal:  J Am Chem Soc       Date:  2008-09-26       Impact factor: 15.419

9.  Quantification of regional myocardial oxygenation by magnetic resonance imaging: validation with positron emission tomography.

Authors:  Kyle S McCommis; Thomas A Goldstein; Dana R Abendschein; Pilar Herrero; Bernd Misselwitz; Robert J Gropler; Jie Zheng
Journal:  Circ Cardiovasc Imaging       Date:  2009-11-20       Impact factor: 7.792

10.  Atrial natriuretic peptide modulation of albumin clearance and contrast agent permeability in mouse skeletal muscle and skin: role in regulation of plasma volume.

Authors:  Fitz-Roy E Curry; Cecilie Brekke Rygh; Tine Karlsen; Helge Wiig; Roger H Adamson; Joyce F Clark; Yueh-Chen Lin; Birgit Gassner; Frits Thorsen; Ingrid Moen; Olav Tenstad; Michaela Kuhn; Rolf K Reed
Journal:  J Physiol       Date:  2009-11-30       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.